Navigation Links
Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
Date:7/5/2011

TUESDAY, July 5 (HealthDay News) -- A drug designed to treat certain patients with non-small cell lung cancer boosts survival time without progression of cancer by several months, according to a new study.

The findings reveal that the drug, known as erlotinib (brand name Tarceva), doesn't just boost lifespan, said Dr. Neal E. Ready, associate professor of medical oncology at Duke Cancer Institute, who was not involved with the study. "What you really get is a prolonged period of time when the cancer is under control and someone has a really good quality of life."

This study is the first of its kind to look at Western patients. "Although a growing body of evidence has been emerging about this type of lung cancer, almost all of the studies have been conducted in Asian patients, a group that historically has had significantly different results to [non-small cell lung cancer] therapy compared to Western populations," said principal investigator Dr. Radj Gervais, of the Centre Francois Baclesse in Caen, France, in a news release from the International Association for the Study of Lung Cancer. The association is hosting the World Conference on Lung Cancer in Amsterdam, where the study results were scheduled for presentation Tuesday.

The study of the drug is a phase 3 study. That means it's in the final of three stages of testing that drugs undergo before they can be approved for treatment of a specific disease.

The researchers randomly assigned 174 patients to either erlotinib or platinum-based chemotherapy. Preliminary results showed that about 55 percent of patients responded to the drug, compared to nearly 11 percent to chemotherapy. Patients lived without progression of cancer for 9.4 months with the drug compared to 5.2 months for those who received chemotherapy.

And the median survival was 22.9 months for those who took the drug compared to 18.8 months for those on chemotherapy, the investigators found.

"Our results showed that first-line erlotinib nearly doubled progression-free survival; that's a significant improvement over chemotherapy, with a better tolerability profile," Gervais said in the news release.

Commenting on the findings, Ready pointed out that the research is important because it shows the value of targeting treatment towards patients with specific types of non-small cell cancer. "In oncology as a field, we're trying to move to identify the right treatment for the right patient," he said.

Erlotinib's side effects -- including an acne-type rash and diarrhea -- are easier to control than those of chemotherapy, he added. As for expense, Ready noted, oral therapies, like this one, tend to be as costly or less expensive than chemotherapy, considering that they cause fewer side effects that need to be managed.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

For more about lung cancer, visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: International Association for the Study of Lung Cancer, news release, July 5, 2011; Neal E. Ready, M.D., associate professor of medical oncology, Duke Cancer Institute, Durham, N.C.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Vaccine Seems to Cure Prostate Cancer in Mice
2. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
3. Ex-Dallas Maverick survives rare form of leukemia thanks to experimental drug treatment
4. Experimental treatment offers relief from painful prostate condition
5. Christos Mantzoros honored by Federation of the American Societies for Experimental Biology
6. Experimental Test May Warn of Premature Births
7. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
8. Experimental Weight-Loss Drug Seems to Work: Study
9. Experimental drug achieves unprecedented weight loss
10. Science at a glance: Symposia, research and special events at Experimental Biology 2011
11. A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
(Date:2/19/2017)... ... 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively ... any logo with a glitch reveal in just a few clicks of a mouse. Customizable ... of each preset. Use these presets to add a uniquely animated logo to any photos ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... ... 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, +1 ... Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical procedure ... been centered around that idea that to achieve ones desired results a surgical ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... South Africa , Feb. 20, 2017  There ... illness and non-communicable diseases (NCDs) across sub-Saharan Africa, which ... drugs. The growing incidence of more Western lifestyle diseases ... disease, in addition to infectious and parasitic illness, will ... with a business opportunity of $40.8 billion in ...
(Date:2/20/2017)... According to a new market research report "Pulmonary/ Respiratory Drug ... dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications ... to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in ... Continue Reading ... ...
(Date:2/20/2017)... --  Alberty   Drugs , a leading ... has announced a significant shift in focus by concentrating ... servicing local Veteran Affairs Centers (VA) and other Federal ... need to secure cost effective treatments for their patients, ... their goods & services. "The opportunity to ...
Breaking Medicine Technology: